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Background: In contrast to drug-sensitive tuberculosis, the guidelines for the treatment of multi-drug-resistant
tuberculosis (MDR-TB) have a very poor evidence base; current recommendations, based on expert opinion, are
that patients should be treated for a minimum of 20 months. A series of cohort studies conducted in Bangladesh
identified a nine-month regimen with very promising results. There is a need to evaluate this regimen in comparison
with the currently recommended regimen in a randomized controlled trial in a variety of settings, including patients
with HIV-coinfection.
Methods/Design: STREAM is a multi-centre randomized trial of non-inferiority design comparing a nine-month
regimen to the treatment currently recommended by the World Health Organization in patients with MDR
pulmonary TB with no evidence on line probe assay of fluoroquinolone or kanamycin resistance. The nine-month
regimen includes clofazimine and high-dose moxifloxacin and can be extended to 11 months in the event of delay
in smear conversion. The primary outcome is based on the bacteriological status of the patients at 27 months
post-randomization. Based on the assumption that the nine-month regimen will be slightly more effective than
the control regimen and, given a 10% margin of non-inferiority, a total of 400 patients are required to be enrolled. Health
economics data are being collected on all patients in selected sites.
Discussion: The results from the study in Bangladesh and cohorts in progress elsewhere are encouraging, but
for this regimen to be recommended more widely than in a research setting, robust evidence is needed from
a randomized clinical trial. Results from the STREAM trial together with data from ongoing cohorts should
provide the evidence necessary to revise current recommendations for the treatment for MDR-TB.
Trial registration: This trial was registered with clincaltrials.gov (registration number: ISRCTN78372190) on
14 October 2010.
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Tuberculosis (TB) that is sensitive to standard drugs is a
curable disease; most patients can be treated effectively
and inexpensively in six months with a regimen that is
based on rifampicin and isoniazid. However, multi-drug-
resistant TB (MDR-TB), a disease that is resistant to iso-
niazid and rifampicin, is much more difficult to treat.
Current treatment of MDR-TB is based on more drugs
given for a much longer time; it is more toxic, has much
less satisfactory outcomes and is more expensive [1,2].
There were an estimated 450,000 cases of MDR-TB
worldwide in 2012, although less than 25% of these
were estimated to have been detected, and fewer still
treated [1]. The diagnosis-treatment gap may be due, in
part, to the absence of an accessible and simple treat-
ment regimen.
In 2011, the World Health Organization (WHO) re-
vised their guidance on the diagnosis and management
of drug-resistant TB [3]. The recommended duration
of the intensive phase was increased to eight months,
and in patients without previous anti-TB treatment a
total duration of a minimum of 20 months was recom-
mended. However, in contrast to recommendations for
treating drug-sensitive TB, both these recommendations
were conditional and were based on ‘very low-quality
evidence’, as were the recommendations regarding the
composition of the regimen [3].
A study carried out in Bangladesh by Van Deun et al.
published in 2010 reported good success rates in a co-
hort of over 200 patients with MDR-TB treated with
a standardized regimen given for only nine months [4].
Such a regimen would have considerable advantages
over standard practice, however, concerns about its
reproducibility and generalizability have limited its
uptake. In light of this, the STREAM trial was set up
with the objective of evaluating the nine-month regimen
in a randomized controlled trial to determine whether
these promising results could be replicated in other set-
tings, and to compare outcomes to those obtained with
the WHO recommended regimen.
This paper describes the design of the STREAM trial,
explaining the background and rationale.
Background
The nine-month regimen studied in Bangladesh
In recent years a number of meta-analyses of the out-
comes of MDR-TB treatment have been published. In a
paper by Orenstein et al. 34 clinical reports with a mean
of 250 patients per report were included in the analysis
[5]. Individualized treatment regimens had a summary
success rate of 64% (95% CI 59 to 68%) defined as cure
or treatment completion; standardized regimens had a
summary success rate of 54% (95% CI 43 to 68%) [5]. A
more recent systematic review found similar results [2],although data published by WHO suggest that the true
success rate for the patients treated with standardized
regimens may well be less than 50% [1].
A prospective observational study conducted over a
12-year period in Bangladesh reported on six successive
cohorts of patients treated for the first time with a stan-
dardized regimen for MDR-TB [4]. The first regimen
was largely based on the 1996 WHO guidelines [6]. Peri-
odic assessment of treatment outcomes, relapses and ad-
verse drug reactions was used to guide the introduction
of changes for subsequent cohorts. The intention was to
develop an effective, safe and inexpensive treatment regi-
men. The sixth treatment regimen proved to be the
most effective; a cohort of 206 patients was treated for a
total of 9 to 12 months, the duration of the intensive
phase being dependent on response at four months on
smear microscopy. Patients were treated throughout
with high-dose gatifloxacin, clofazimine, ethambutol and
pyrazinamide supplemented by prothionamide, kanamy-
cin and double-dose isoniazid during the four-month
intensive phase. The relapse-free cure rate was 87.9%
(95% CI 82.7 to 91.6) [4].
The Bangladesh project targeted maximum effective-
ness rather than efficacy. Drugs such as PAS (4-aminosa-
licylic acid) and cycloserine, whose activity is offset by
toxicity and poor tolerability, were therefore avoided,
and other more active drugs that are also difficult to
tolerate, such as prothionamide, were limited to the in-
tensive phase [7]. These were added to a foundation of
selected first-line drugs that might be expected to work
in at least some patients: ethambutol, isoniazid and pyra-
zinamide. High doses of selected drugs were used in an
effort to maximize effectiveness. In an experimental
model it has been shown that selection of resistant mu-
tants could be avoided by using high-dose moxifloxacin
[8]. A moderately high isoniazid dose was chosen to
overcome at least the low-level resistance conferred by
the inhA mutation causing cross-resistance to the thioa-
mides, without provoking excessive adverse effects. In-
clusion of clofazimine in the regimen as a potentially
effective drug was based on in vitro testing, although it
has never been properly assessed in humans, and cell
and animal models have yielded contradictory results.
Additional arguments for inclusion of clofazimine were
its lack of known serious toxicity from long-term use for
leprosy, and a possible synergy with isoniazid [9].
An additional over-riding objective was to avoid ampli-
fication of resistance and the creation of XDR-TB; XDR-
TB is defined as TB that has developed resistance to
rifampicin and isoniazid as well as to any member of
the quinolone family and at least one of the following
second-line anti-TB injectable drugs: kanamycin, capreo-
mycin, or amikacin. It was felt that prolonged use of less
potent drugs would have this effect in cases failing to
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men appears to have been successful in this regard; only
one case of XDR was created in a strain initially suscep-
tible to injectables and clofazimine among over 500 pa-
tients enrolled between 2005 and 2011 in Bangladesh
[10,11]. High cure rates of MDR-TB were achievable
only with the introduction of fluoroquinolones [12]. The
second-line injectables were thus not considered as core
drugs, but only as powerful companion drugs protecting
the fluoroquinolones. When they fail to do so within
the first months of treatment, resistance will be ac-
quired, first to the fluoroquinolones and subsequently to
second-line drugs as well. Moreover, limiting their dur-
ation to the point of smear-conversion or early declaration
of treatment failure would also limit their dose-dependent
ototoxicity. The same reasoning applied to the thioamides
(prothionamide and ethionamide), and indeed, not a single
case of acquired resistance to these drugs was found
among the Bangladesh recurrences.
The treatment duration of the regimen was set at nine
months based on the improved sterilizing activity of
the fourth generation fluoroquinolones in the mouse
model [9], and the total absence of relapse in previous
Bangladesh cohorts treated for 15 months with ofloxacin
(a drug with an inferior sterilizing capability).
The need to assess the nine-month Bangladesh regimen
in other settings
The promising results from Bangladesh prompted a
2008 external review of the pilot study, initiated by
the International Union Against Tuberculosis and Lung
Disease (The Union), and led by the World Health
Organization (WHO). The external review concluded
that additional evidence from larger studies was needed
in order to determine whether scale-up of a nine-month
regimen could be recommended in less controlled con-
ditions. Additionally, the review concluded that this
should preferably be done in randomized controlled
clinical trials conducted under the requirements of
Good Clinical Practice (GCP). It was also considered
important to assess the regimen in the presence of
HIV-coinfection. The Union’s response to these recom-
mendations was to mobilize resources to undertake
such a clinical trial.
In April, 2008, shortly after the results of the external
review were reported by the WHO, the United States
Agency for International Development (USAID) released
a request for proposals for ‘Tuberculosis Research to
Enhance the Prevention, Detection, and Management of
TB cases’. A multi-site clinical trial to determine the op-
timal use of existing drugs for MDR-TB treatment was
highlighted as a key component of the research agree-
ment. The Union, with a team of international and re-
gional partners, successfully responded to the requestfor proposals with the five-year Cooperative Agreement
in September, 2008. A priority within the initial work
plan of the Agreement was the implementation of a clin-
ical trial to evaluate the Bangladesh regimen. In collabor-
ation with the Medical Research Council Clinical Trials
Unit at University College London (United Kingdom), the
STREAM trial was designed and initiated. There were a
number of important logistical issues to overcome before
the trial could start, including determining the most suit-
able trial design and protocol, procurement of the study
regimen medicines and supplies and securing the neces-
sary global- and country-level authorizations and ap-
provals. The trial opened to recruitment in July 2012.
Primary objectives
The primary objectives of the STREAM trial are two-
fold. Firstly, to assess whether the proportion of patients
with a favorable efficacy outcome on the nine-month
study regimen is not inferior to that on the control
(WHO-approved MDR-TB) regimen. Secondly, to com-
pare the proportion of patients who experience a grade
3 or greater adverse event (using the Division of AIDS
criteria for grading the severity of adverse events) during
treatment or follow-up in the nine-month regimen as
compared to the control regimen.
Methods
Choice of study regimen and choice of comparator
The intention of the study was to evaluate the safety and
efficacy of the Bangladesh regimen in a randomized con-
trolled trial in comparison to the WHO recommended
standard of care. The nine-month study regimen con-
sists of moxifloxacin, clofazimine, ethambutol and pyra-
zinamide given for nine months (40 weeks), supplemented
by kanamycin, isoniazid and prothionamide in the first
four months (16 weeks). All drugs are given in a single
dosage daily (seven days a week) except for kanamycin
which is given three times per week from week 12. The in-
tensive phase can be extended from 16 to 20 or 24 weeks
for patients whose smear has not converted by 16 or
20 weeks respectively. The control regimen is the locally-
used WHO-approved MDR-TB regimen. One modifica-
tion had to be made to the nine-month regimen described
by Van Deun et al. [4] due to the limited global availability
of gatifloxacin manufactured to Good Manufacturing
Practice standards at the time the study was being devel-
oped. Alternative fluoroquinolones were all considered
and it was decided to employ moxifloxacin on the basis of
its similarity to gatifloxacin in terms of bactericidal activity
at the same dose [13,14]. It was recognized that the doses
of moxifloxacin which would be used for patients in the
higher weight bands were not standard and might carry an
increased risk of adverse effects, and that careful safety
monitoring would be essential. Table 1 shows the doses of
Table 1 nine-month study regimen drugs and doses
Product Weight group
Less than 33 kg 33 to 50 kg More than 50 kg
Moxifloxacin 400 mg 600 mg 800 mg
Clofazimine 50 mg 100 mg 100 mg
Ethambutol 800 mg 800 mg 1200 mg
Pyrazinamide 1000 mg 1500 mg 2000 mg
Isoniazid* 300 mg 400 mg 600 mg
Prothionamide* 250 mg 500 mg 750 mg
Kanamycin* 15 mg per kilogram body weight (maximum 1 g)
*Given only during the 16-week intensive phase which can be extended to 20
or 24 weeks in the event of delayed smear conversion.
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ated in the STREAM trial. The replacement of gatifloxacin
with moxifloxacin at the same dose is the only modifica-
tion from the regimen studied in Bangladesh.
Since the regimen being studied is standardized, in
contrast to individualized regimens which are tailored to
an individual’s particular drug sensitivity results, it would
be most relevant to settings where standardized regi-
mens are used. Therefore, a standardized regimen that
followed WHO recommendations was considered an ap-
propriate comparator. WHO recommendations are
guidelines which include some latitude in their imple-
mentation, resulting in different regimen compositions
in different settings. Mandating any one particular stan-
dardized regimen as the comparator for the trial would
be a departure from standard of care for some treatment
programs and therefore not deemed a reasonable com-
parison. It was therefore decided that the control regi-
men for the STREAM trial should be the locally
mandated standardized regimen in use at the study site
provided that it complied with WHO guidelines. This
regimen does vary by site, but since randomization in
the trial is stratified by site, valid inference can still be
made using data from the whole study population.
Site selection
The selection of sites for the STREAM trial was under-
taken in three stages. The initial selection of potential
countries followed predefined criteria. These included:
sufficiently high overall MDR-TB burden (including both
diagnosed MDR-TB cases and estimated MDR-TB cases),
a well-functioning basic treatment program (using low
default- and low transfer out-rates as proxy measures), the
presence of a Green Light Committee (GLC) approved
treatment site which would ensure satisfactory control
regimen implementation and the presence of TB-HIV
treatment activities to ensure adequate management of
TB-HIV co-infection within the trial. The GLC is a WHO
committee set up to promote access to and rational use ofsecond-line anti-tuberculosis drugs. Furthermore, given
the intent for a pragmatic and programmatic-based trial,
the entry point for site assessment was the national tuber-
culosis programs (NTP) of selected countries. Only upon
acceptance of the concept by a representative of the NTP
and a commitment from the NTP that successful trial
results would result in consideration of the regimen for
the program was further site assessment and evaluation
conducted.
Following a determination of country suitability based
on the criteria specified, a site questionnaire was com-
pleted by a program representative. Information requested
included: number of cases diagnosed and number initiated
on treatment in the previous year, patient management
practices such as hospitalization and measures to ensure
adherence and anticipated proportion of MDR-TB patients
who would be eligible for STREAM based on the inclusion
and exclusion criteria.
Finally, where the site questionnaire suggested likely
suitability for the trial, a site assessment visit was con-
ducted. The site visits assessed capacity to implement a
clinical trial, strength of MDR-TB clinical management
and laboratory capacity with respect to trial laboratory
procedures. Other trial-related components, such as
pharmaceutical services and data management facilities
were also assessed. The ultimate decision to include a site
in the trial was based on the findings of the site assess-
ment visit.
Patient eligibility criteria
Apart from willingness to participate in the clinical trial,
the main eligibility criterion is rifampicin resistance
demonstrated by drug susceptibility testing (DST). Ac-
ceptable methods of DST for this purpose are line-probe
assay (LPA), Xpert MTB/RIF or conventional phenotypic
testing. Since patients infected with rifampicin-resistant
but isoniazid-sensitive organisms are commonly man-
aged in the same way as patients with MDR-TB and
evidence of isoniazid resistance is not necessary for in-
clusion in the trial. Patients with strains showing resist-
ance to fluoroquinolones and/or second line injectables
on rapid LPA are not eligible. While lacking sensitivity
[15], it was felt that this test would at least allow exclu-
sion of highly resistant cases in danger of resistance
amplification to XDR-TB, without excessively delaying
enrolment and start of treatment. Patients in critical
condition and those with pre-existing liver disease with
aspartate transaminase (AST) or alanine aminotransfer-
ase (ALT) greater than five times the upper limit of nor-
mal, or corrected QT interval (time between the start of
the Q wave and the end of the T wave in the heart’s elec-
trical cycle) of greater than 500 ms, are also excluded be-
cause of the limited safety information on the regimen.
Premenopausal women are required to use effective barrier
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during the treatment phase and pregnant or breastfeeding
women are excluded. All participants are required to have
an HIV test and, if positive, to be treated with anti-
retroviral treatment (ART) in accordance with the national
policies.
Recruitment process
Potentially eligible patients are referred to study sites for
screening to ascertain whether they satisfy the eligibility
criteria for enrolment. At their first visit, the study is ex-
plained, including the potential risks and benefits associ-
ated with participation. Informed consent is obtained
before any protocol-specific screening procedures are
carried out. Each patient is asked to sign (or provide a
thumbprint in the presence of a witness if illiterate) for
the screening procedures and is given a copy of the
signed consent form and a patient information sheet to
take home.
Investigations undertaken include sputum samples for
smear, rifampicin resistance testing by LPA or GeneXpert
(unless there is a result from another reliable source in-
dicating resistance), LPA for second-line injectables and
fluoroquinolone if rifampicin resistant. Blood samples
are obtained for HIV antibodies (unless the patient is
already known to be HIV positive) and liver function
tests (AST and ALT).
Patients are re-assessed for eligibility in the light of the
results of the laboratory tests when they return after
their screening visit. The time between the screening
and enrolment visits is kept as short as logistically pos-
sible, but must be no more than four weeks; those
returning after four weeks must be re-screened prior to
enrolment.
Treatment allocation
Allocation of treatment for eligible patients is web-based
and controlled through an authorized user name and
password. Separate randomization lists for each combin-
ation of strata (site and HIV status) are prepared in ad-
vance by a statistician independent of the study, using
varying block sizes. Should web access not be available
at the time of randomization, a manual alternative using
sealed envelopes is available. The opaque sealed enve-
lopes are kept in a locked box by the local trial pharma-
cist. Patients are enrolled only after they are found to
have satisfied all the enrolment criteria.
Blinding to treatment assignment
Because of the nature of the trial interventions it is im-
possible to conduct the trial blind to treatment alloca-
tion to the participants, care givers or data managers.
All laboratory assessments, including microbiological as-
sessments which form the basis of the patient’s outcome,are conducted blind within both the local and reference
laboratories. We accept that local physicians may be in-
fluenced in their decision as to whether treatment
changes should be made by the knowledge of the treat-
ment allocation. For this reason we have requested that be-
fore any changes are made the local physician discusses
them with the central medical team (see section below).
Duration of follow-up and assessment of the
primary outcome
One of the major design challenges of the trial was to
identify the most appropriate timing for the primary out-
come, considering the very different durations of the
regimens. In recognition of the fact that patients allo-
cated to the control regimen might receive up to
24 months of treatment it was decided to set the primary
outcome as status at 27 months post-randomization,
which is very soon after the end of treatment for the con-
trol regimen but 18 months after the end of the study
regimen. This could potentially result in bias in favor of
the control regimen since there is less time after the end
of treatment for patients to relapse. Follow-up is every
four weeks throughout the trial for patients on both
arms. At each assessment sputum samples are collected
for smear and culture examination. Positive isolates are
sent to the study reference laboratory, the Institute of
Tropical Medicine in Antwerp (Belgium), for drug sensi-
tivity testing and strain typing for distinguishing relapses
from reinfections.
A single isolated positive culture detected in a clinical
trial cannot be assumed to be indicative of treatment
failure or relapse [16]. While there is much experience
of defining failure and relapse in trials of drug sensitive
TB [17], there is no such clear guidance for trials in
MDR-TB, and often the treating clinician is best placed
to determine whether a patient is failing treatment or
relapsing based on a combination of clinical and micro-
biological data. For this reason, the definition of the pri-
mary outcome is driven not only by the culture results,
but also by changes to, or restarting of treatment.
Any of the following constitute an unfavorable out-
come: positive culture results at 27 months, a change of
two or more drugs in the assigned regimen or extension
beyond replacement of any missed treatment, restarting
treatment or death from any cause during treatment or
follow-up. Furthermore, patients who are lost to follow-
up before 15 months post-randomization will be consid-
ered to have an unfavorable outcome. Those lost after
15 months whose two previous culture results were
negative will be considered not assessable in the primary
analysis and unfavorable otherwise. Patients who are
culture-negative at 27 months will be classified as having
a favorable outcome unless they have been otherwise
classified as unfavorable.
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The objective of assessing the nine-month regimen in a
range of settings could have been addressed in a number
of different ways. One way would have been to prospect-
ively enroll further observational cohorts in a number
of different countries and report on outcomes. How-
ever, unlike the standard six-month regimen for drug-
sensitive TB which has been extensively studied in
clinical trials in a wide variety of settings with consistent
results [15], there is a paucity of data from controlled tri-
als or well-conducted cohort studies of treatment for
MDR-TB from which a relatively accurate estimate could
be derived to serve as an external comparator; besides
which results from observational cohorts are often difficult
to evaluate because of selection biases. The alternative for
providing high-quality evidence for the efficacy and safety
of the nine-month regimen was to conduct a randomized
controlled trial in which patients were to receive either the
nine-month regimen or the WHO recommended stan-
dardized regimen, and this was therefore the approach that
was chosen for the STREAM trial.
Currently reported treatment outcomes of MDR-TB
are unsatisfactory [1]. If it were to be assumed that the
control regimen was 65% effective and the nine-month
regimen 85% effective, similar to what was found in
Bangladesh, fewer than 220 patients would be required
to demonstrate superiority with 90% power. These as-
sumptions, however, are likely to be unrealistic under
trial conditions since the standardized regimen is likely
to perform better than the average success rate reported
in the systematic reviews and the Bangladesh regimen
might not perform as well outside of Bangladesh. Using
more realistic assumptions of 70% favorable outcomes
for the control and 75% for the nine-month regimen, the
numbers required for a superiority comparison, even
with only 80% power, would be over 1000 per arm, lead-
ing to a trial that would take many years to enroll
thereby greatly delaying the results. However, even if a
nine-month regimen that was much shorter, less expen-
sive with fewer side effects was shown to be no worse
(non-inferior) to the standard regimen, this would be a
major advance. The STREAM trial therefore has a non-
inferiority design with the primary objective being to
evaluate whether the nine-month regimen is non-inferior
to the WHO standardized regimen.
It is assumed for the power calculations that the nine-
month regimen is 5% superior to the control WHO
regimen (75% versus 70% favorable outcome). Given a
non-inferiority margin of 10% and an assumption that as
many as 20% of patients will not be assessable in the pri-
mary analysis (see below for discussion of this category),
then a total of no more than 400 patients would be re-
quired to demonstrate non-inferiority, with 80% power
and 5% significance (two-sided). Twice as many patientsare allocated to the study regimen as to the control regi-
men in order to collect more data on the efficacy and
safety on this regimen. In the event that non-inferiority
were to be demonstrated, it would be appropriate to for-
mally evaluate whether the nine-month regimen was
superior, although the power to do so would be low un-
less the difference was large.
Analysis of the primary endpoints
For the primary efficacy analysis, the difference in pro-
portion of favorable outcomes between the control regi-
men and the nine-month regimen with 95% confidence
intervals will be estimated. The analysis will be stratified
by the randomization stratification factors, site and HIV
status. The upper bound of the 95% confidence interval
of the difference in proportion favorable between the
control and nine-month regimens must be less than 10%
(the margin of non-inferiority) in both the modified
intention-to-treat (mITT) and the per protocol (PP)
populations for the nine-month regimen to be declared
non-inferior to the control.
Because of the substantial difference in treatment dur-
ation we expect it to be harder to retain patients receiv-
ing the shorter duration regimen for the duration of
the follow-up period. This increases the chance that
these patients will be classified as unfavorable or as
unable to be assessed, potentially biasing the results
towards failure to declare non-inferiority of the nine-
month regimen.
Secondary efficacy analyses include sensitivity analyses
to assess the consistency of findings, results in pre-
specified subgroups such as HIV-infected patients and
an analysis based only on the long-term bacteriological
status, irrespective of any changes or modifications of
allocated treatment.
The primary safety outcome is the occurrence of grade
3 or greater adverse events as evaluated by the Division
of AIDS criteria for grading the severity of adverse
events. This analysis will be repeated in subgroups ac-
cording to HIV infection status and drug resistance
patterns.
The central medical team
First-line anti-tuberculosis drugs are in general well-
tolerated with a relatively low frequency of major ad-
verse events. Other drugs used in the treatment of
MDR-TB are in general more toxic than those given for
drug-sensitive TB. A very high proportion of MDR-TB
patients (up to 70% in several reports) on second-line
anti-tuberculosis drugs experience one or more adverse
drug reactions [18,19], the management of which is one
of the most challenging aspects of MDR-TB treatment.
Although most of these side effects are relatively minor,
some are serious, either life-threatening or potentially
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renal toxicity, optic neuritis, ototoxicity, severe neuro-
logical or psychiatric disturbance), and may require that
the responsible drugs are permanently removed from
the regimen. To date, there have been few clinical trials
that provide information to guide the management of
patients with adverse drug reactions in MDR-TB. Thus,
the evidence base for guidelines to assist the clinical
management of patients who experience adverse drug
reaction is lacking. In most cases, management relies
on clinical judgment and experience, balancing the risks
of continuing toxic treatment compared to the risks
associated with the use of less efficacious drugs. The
clinician has to try to judge whether it is better to
interrupt treatment temporarily to safeguard patient
safety, whether it is safe to re-introduce potential toxic
drugs after temporary interruption of treatment, how to
select the optimal timing and sequence in the re-
establishment of an effective regimen and whether it is
necessary to add new drugs if one or more drugs are
withdrawn from the treatment regimen. If healthcare
workers are not familiar with, or not well-trained in the
management of adverse effects of the anti-tuberculosis
drugs, they may discontinue treatment unnecessarily,
re-introduce drugs with suboptimal timing, add new
drugs to the treatment regimen unnecessarily or ter-
minate treatment prematurely.
As treatment change is closely linked to outcome as-
sessment in the STREAM trial, and clinicians in trial
sites may have different experience and approaches in
the management of patients with adverse drug reactions,
it was decided to establish a central medical team to
provide clinical guidance on the management of patients
with adverse drug events to promote consistent manage-
ment across sites.
The central medical team is an international panel
with expertise in MDR-TB treatment, antiretroviral ther-
apy, clinical microbiology and electrocardiology. The
panel works remotely, communicates primarily by email
with occasional face-to-face meetings and is coordinated
by the clinical co-chief investigator. Site investigators
may request advice on any clinical issues, but are asked
to inform the central clinical team if they think it may
be necessary to make a change to the treatment regimen
the patient is receiving. The co-chief investigator will
request the central medical team to provide input on
how to manage the patients. The central medical team is
asked to provide comments in a timely manner (usually
within 1 to 2 days) to ensure efficiency in the manage-
ment of patients with adverse drug events. The coordin-
ator integrates the expert advice of the central medical
team and forwards it to the site principal investigator.
However, it is purely advice and the decisions about clin-
ical management of the patients remain with the siteprincipal investigator. Communication between trial sites,
the co-principal investigator and the central medical team
continues till the problem is resolved.
QT monitoring and the management of QT prolongation
The inclusion in the STREAM regimen of high doses of
moxifloxacin, which is known to cause QT prolongation
[20], together with the fact that many of the patients
would also be taking antiretroviral medication which
might also impact QT, made the careful monitoring of
the cardiac effects of the regimen essential. The protocol
requires each patient to have a 12-lead electrocardio-
gram (ECG) prior to randomization, and anyone with a
corrected QT interval (QTc) of 500 ms or greater is not
eligible for the study. Further 12-lead ECGs are under-
taken at two and four hours after the first treatment
dose, then weekly for the first four weeks and at the end
of weeks 12, 24 and 36. This was subsequently changed
to four-weekly for one year. A 24-hour Holter ECG is
undertaken the first time the 12-lead QTc is ≥450 ms
(the upper limit of normal for men and below the upper
limit of normal for women [21,22]) to identify diurnal
variation which takes the QTc over 500 ms. If the QTc is
confirmed as being over 500 ms the cause is sought, and
if the patient is on high-dose moxifloxacin the dose is
adjusted or levofloxacin substituted to bring the QTc
to <500 ms.
Sites are provided with standardized ECG equipment
with automatic reporting facilities and a cardiologist is a
member of the central medical team and is available to
review ECGs of concern. An independent data monitor-
ing committee (IDMC) including two infectious diseases
clinicians, a cardiologist and two statisticians has been
formed which reviews efficacy and safety data at six-
monthly intervals including data on QT prolongation.
Health economic assessment
The diagnosis and treatment of TB imposes a substantial
economic burden on both health systems and patients.
This is of particular concern given the prevalence of
TB in countries with limited resources, and among the
poorest populations in those countries. The economic
burden of MDR-TB is particularly acute, given the dur-
ation and intensity of treatment. Even when treatment is
free, patients face substantial direct and indirect costs
when accessing TB services [23]. This financial burden
has been linked with poor adherence, and may have se-
vere long-term implications for the financial security of
patients and their families, particularly among the highly
disadvantaged groups who form a large proportion of
TB patients.
Shorter treatment regimens have the potential to re-
duce the burden of MDR-TB treatment on patients
and health systems. However, the impact will depend on
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rates. The economic impact of shorter treatment regi-
mens will also depend on the timing of patient and
health-system costs; they will have a greater impact if
costs are evenly distributed rather than ‘front-loaded’
[24]. An understanding of the health economics of al-
ternative MDR-TB regimens is therefore required by
policymakers planning TB services and social protec-
tion programs for TB patients. With this in mind, col-
lection of data on health system resource use and
patient costs has been incorporated into the STREAM
study design.
Every patient recruited into selected sites of the main
study is asked to participate in the health economic
component of the study. Data are collected on costs
incurred in adhering to the regimen, as well as those re-
lated to the management of adverse events. Data are col-
lected at recruitment and every three months thereafter,
and includes socioeconomic status, education, employ-
ment, housing and ownership of physical assets and the
costs of food, transport and medications.
The impact of alternative regimens on healthcare re-
source use are being assessed by identifying the pro-
cesses and activities involved in the delivery of each
regimen, and the management of adverse events. The re-
sources used in staff time, consumables and fixed assets
are identified and measured. Unit costs are collected to
allow calculation of the total health system cost for each
regimen. Data are collected by interviewing appropriate
personnel and from records held by funders and health-
care providers.
Ethical approval
The trial received ethical approval from the Ethics
Advisory Group of the International Union Against
Tuberculosis and Lung Disease (approval number 07/11)
and from the ethics committees of each of the partici-
pating sites, namely: South African Medical Research
Ethics Committee (approval number EC011-8/2011),
Wits Health Consortium Protocol Review Committee
(approval number 110602), the Ethics Committee of
the Socialist Republic of Vietnam (approval number
661/QD-BYT), St Peter TB Specialized Hospital Ethical
Review Committee, Addis Ababa and AHRI-ALERT
Ethical Review Committee, Addis Ababa (approval number
PO 23/11).
Dissemination of trial findings
Results of the trial will be published in peer-reviewed
journals in accordance with the Consort 2010 statement
including the extension for non-inferiority trials [25,26].
Findings will be presented at international and na-
tional conferences, shared with local health ministries
and with departments of WHO and other internationalorganizations responsible for producing guidelines for
the treatment of MDR-TB.Discussion
In 1971 Cochrane gave TB the accolade of having the
best evidence base for treatment of any disease and went
on to say that the way in which new treatments for TB
were introduced could serve as a model for all new
treatments in future [27]. Unfortunately this can no
longer be said to be true for TB and certainly not for
MDR-TB. The WHO readily admit to the very low qual-
ity of evidence underpinning their guidelines for treating
MDR-TB because of the complete lack of late-stage ran-
domized clinical trials [3].
The research program conducted in Bangladesh by
the Damien Foundation provides excellent systematically
collected data for the effectiveness of a series of regi-
mens studied not in a randomized design but in con-
secutively recruited cohorts [4]. The results obtained
from the sixth cohort of over 200 patients were impres-
sive, but opinion was divided as to the impact of poten-
tial biases that are always present in observational
studies and whether these results could be replicated in
different settings. The STREAM trial is evaluating, in a
randomized controlled non-inferiority trial, whether the
nine-month regimen can be considered to be at least as
good, if not better, than the regimen recommended by
WHO. Because of the long duration of the latter regi-
men of 20 to 24 months, and because enrolment to
STREAM is not expected to complete before the end of
2014, it will inevitably be several years before the out-
come of the trial is known. In the meantime additional
cohorts assessing a regimen the same or similar to that
studied in Bangladesh are being enrolled in several
counties, mainly from sub-Saharan Africa [28,29]. One
advantage of this parallel assessment will be that when
the trial results are reported there will be additional data
from studies conducted under program conditions.
Phase III clinical trials in MDR-TB take many years
to conduct and are expensive. Without good surrogate
markers, however, they remain necessary to provide
reliable evidence to inform policymakers and give
confidence to their recommendations, although credit
must be given to the Bangladesh study for identifying
the nine-month regimen and generating the hypoth-
eses that are being critically evaluated in the STREAM
trial.Trial status
Recruitment began at the first site in July 2012 and is ex-
pected to be completed by early 2015. Discussions are
taking place about the possibility of adding additional
arms to a second stage of the STREAM trial.
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